DBV Technologies SA
OTC:DBVTF
DBV Technologies SA
OTC:DBVTF
Price:
4.7996
USD
Market Closed
Market Cap:
$657.3m
Relative Value
The Relative Value of one
DBVTF
stock under the Base Case scenario is
0.0003
USD.
Compared to the current market price of 4.7996 USD,
DBV Technologies SA
is
Overvalued by 100%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DBVTF
Relative Value
Base Case
0.0003
USD
Overvaluation 100%
Multiples Across Competitors
DBVTF Competitors Multiples
DBV Technologies SA Competitors
DBV Technologies SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
DBV Technologies SA
OTC:DBVTF
|
1B USD | 319.4 | -9.9 | -9.4 | -9.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.4B USD | 6.7 | 97.8 | 16 | 22.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.3B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.1B USD | 6.1 | 21.1 | 13.2 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.8B USD | 9.8 | 29.6 | 22.3 | 23.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81B USD | 5.6 | 18 | 13.4 | 15.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.8B AUD | 3.2 | 35.6 | 11.7 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.7B EUR | 10.9 | 35.1 | 38.1 | 38.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
